2016 Update
Key population
Guidelines
Key Populations
Putting Asia’s HIV response back on track
UNAIDS Series: Engaging uniformed services in the fight against AIDS - Case Study 1
Fighting AIDS
From choice, a world of possibilities
Par ses propriétés thérapeutiques, le médicament permet aux professionnels de santé
ainsi quaux pouvoirs publics dassurer la santé des populations. De ce fait, sa disponibilité et
son efficacité sont essentielles et sont le résultat dun circuit complexe (de sa fabrication... à sa
destruction en passant par sa distribution).
Laccessibilité au médicament est un élément déterminant de toute politique de santé.
Elle est garantie par la politique pharmaceutique de chaque pays qui vise à rendre le
médicament disponible pour tous, sur lensemble du territoire (accessibilité géographique), à
tout moment (accessibilité physique), à un prix abordable (accessibilité financière) et en
garantissant son efficacité et sa qualité (accessibilité qualitative
more
Int J Health Policy Manag 2017, 6(10), 587–600
Low-income countries face many contextual challenges to manage healthcare technologies effectively, as the majority are imported and resources are constrained to a greater extent. Previous healthcare technology management (HTM) policies in Benin ha...ve failed to produce better quality of care for the population and cost-effectiveness for the government. This study aims to identify and assess the main problems facing HTM in Benin’s public health sector, as well as the ability of key actors within the sector to address these problems.
more
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
Guidelines
June 2017
HIV strategic information for impact
WHO working group on HIV incidence assays meeting report
10–11 December 2015
Glion, Switzerland
UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
WHO/HIV/2017.03
Product:BDFACSCountTM InstrumentSystemwithFACSCountTM ControlKitandBD FACSCountTM CD4ReagentKit(AbsoluteandPercentageCD4+Counts)
Number: PQDx 0133-045-00
0133-045-00 WHO
PQDx PR
June/2016, version 2.0
PQDx 0197-045-00 WHO
PQDx PR
March /2016, version 2.0
PQDx 0181-031-00
WHO PQ Public Report
March/2017, version 3.0